8098 related articles for article (PubMed ID: 2306755)
1. Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia.
Rajaram N; Tatake RJ; Advani SH; Naik SL; Gangal SG
Cancer Immunol Immunother; 1990; 31(1):44-8. PubMed ID: 2306755
[TBL] [Abstract][Full Text] [Related]
2. BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells.
Roger R; Issaad C; Pallardy M; Léglise MC; Turhan AG; Bertoglio J; Bréard J
Blood; 1996 Feb; 87(3):1113-22. PubMed ID: 8562937
[TBL] [Abstract][Full Text] [Related]
3. Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity.
Verfaillie C; Miller W; Kay N; McGlave P
Blood; 1989 Aug; 74(2):793-7. PubMed ID: 2473805
[TBL] [Abstract][Full Text] [Related]
4. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia.
Verfaillie C; Kay N; Miller W; McGlave P
Blood; 1990 Jul; 76(2):401-8. PubMed ID: 1695114
[TBL] [Abstract][Full Text] [Related]
5. Endogenous lymphokine activated killer cell activity and cytogenetic response in chronic myelogenous leukaemia treated with alpha-interferon.
Meseri A; Delwail V; Brizard A; Lecron JC; Pelletier D; Guilhot F; Tanzer J; Goube de Laforest P
Br J Haematol; 1993 Feb; 83(2):218-22. PubMed ID: 8457470
[TBL] [Abstract][Full Text] [Related]
6. Natural killer (NK) and lymphokine-activated killer (LAK) activities in a patient who recovered from cancer, and the characteristics of LAK cells generated from CD4-CD8- and CD8+ peripheral blood lymphocytes.
Komatsu F; Kihara K
Clin Immunol Immunopathol; 1995 Oct; 77(1):75-81. PubMed ID: 7554487
[TBL] [Abstract][Full Text] [Related]
7. Natural killer and lymphokine activated killer cell functions in Hodgkin's disease.
Rajaram N; Tatake RJ; Advani SH; Gangal SG
Br J Cancer; 1990 Aug; 62(2):205-8. PubMed ID: 2386735
[TBL] [Abstract][Full Text] [Related]
8. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
9. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.
Silla LM; Pincus SM; Locker JD; Glover J; Elder EM; Donnenberg AD; Nardi NB; Bryant J; Ball ED; Whiteside TL
Br J Haematol; 1996 May; 93(2):375-85. PubMed ID: 8639431
[TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killer cell functions in patients with leukemic B-lymphoproliferative diseases.
van der Harst D; Brand A; van Luxemburg-Heys SA; Kooy-Winkelaar EM; van Rood JJ
Blood; 1989 Nov; 74(7):2464-70. PubMed ID: 2804374
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
Teichmann JV; Ludwig WD; Thiel E
Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
[TBL] [Abstract][Full Text] [Related]
12. [Cytolytic activity by lymphokines (LAK activity) in chronic myeloid leukemia].
Cervantes F; Miller JS; McGlave PB
Med Clin (Barc); 1995 Jun; 105(2):50-3. PubMed ID: 7603094
[TBL] [Abstract][Full Text] [Related]
13. Effects of alpha-interferon on MHC unrestricted cytotoxicity in chronic myelogenous leukemia.
Meseri-Delwail A; Delwail V; Brizard A; Goube de Laforest P; Guilhot F; Lecron JC
Biotechnol Ther; 1994; 5(1-2):47-57. PubMed ID: 7703832
[TBL] [Abstract][Full Text] [Related]
14. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
[TBL] [Abstract][Full Text] [Related]
15. PGE2, but not TGF beta 2, in rabbit blastocoelic fluid regulates the cytotoxic activities of NK and LAK cells.
Bergeron D; Ouellette MJ; Lambert RD
J Reprod Immunol; 1997 Jul; 33(3):203-19. PubMed ID: 9255724
[TBL] [Abstract][Full Text] [Related]
16. The heterogeneity of target recognition by lymphokine-activated killer precursor cells.
Ibayashi Y; Gray JD; Golub SH; Daibo M; Yamaki T; Kawahara T; Kubota T; Hashi K
Jpn J Cancer Res; 1990 Sep; 81(9):927-35. PubMed ID: 2121694
[TBL] [Abstract][Full Text] [Related]
17. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha.
Pawelec G; Da Silva P; Max H; Kalbacher H; Schmidt H; Bruserud O; Zügel U; Baier W; Rehbein A; Pohla H
Leuk Lymphoma; 1995 Aug; 18(5-6):471-8. PubMed ID: 8528055
[TBL] [Abstract][Full Text] [Related]
18. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.
Subauste CS; Dawson L; Remington JS
J Exp Med; 1992 Dec; 176(6):1511-9. PubMed ID: 1460415
[TBL] [Abstract][Full Text] [Related]
19. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
Pierson BA; Miller JS
Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
[TBL] [Abstract][Full Text] [Related]
20. Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission.
Dabholkar M; Tatake R; Amin K; Advani S; Gangal S
Oncology; 1989; 46(2):123-7. PubMed ID: 2785254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
